Clearmind MedicineCMND
CMND
About: Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Employees: 4
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,891% more capital invested
Capital invested by funds: $276K [Q2] → $5.49M (+$5.22M) [Q3]
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 [Q2] → 8 (+4) [Q3]
12.29% more ownership
Funds ownership: 5.01% [Q2] → 17.3% (+12.29%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for CMND.
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odorless, made from natural ingredients, and designed to be sprinkled on meals. The two companies plan to collaborate on the development and commercialization of Clearmind's proprietary MEAI-based alcohol substitute and Dr Glitter Pty Ltd's proprietary ActivCrystal™ technology.
Neutral
GlobeNewsWire
2 months ago
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval from one of its clinical sites in the U.S. for part A of its Phase I/IIa clinical trial in the United States for treating patients suffering from alcohol use disorder (AUD). The multinational, multi-center trial will assess the safety, tolerability, and pharmacokinetics of Clearmind's innovative MEAI-based (5-methoxy-2-aminoindane) treatment, CMND-100.
Neutral
GlobeNewsWire
3 months ago
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care
Neutral
GlobeNewsWire
3 months ago
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty (“PCT”).
Neutral
GlobeNewsWire
3 months ago
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments
Neutral
GlobeNewsWire
3 months ago
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application under the international Patent Cooperation Treaty (“PCT”) for innovative combinations of Ketamine and N-Acylethanolamines.
Neutral
GlobeNewsWire
4 months ago
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.
Neutral
GlobeNewsWire
4 months ago
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company's ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.
Neutral
GlobeNewsWire
4 months ago
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem.
Neutral
GlobeNewsWire
4 months ago
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
Vancouver, Canada, July 31, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today concluded its successful participation at the Psychedelic Medicine – Israel 2024 conference. The event took place in Tel Aviv, Israel, bringing together leading experts and researchers from around the world in the field of psychedelic medicine.
Charts implemented using Lightweight Charts™